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Cetuximab-Induced Aseptic Meningitis
Nail Nagovskiy, MD, Manoj Agarwal, MD, and Jeffrey Allerton, MD
Several phase III trials demonstrated a statistically im-proved outcomes with cetuximab in patients with non-
small cell lung carcinoma (NSCLC) expressing epidermal
growth factor receptor (EGFR).1 Here, we describe two
cases of drug-induced aseptic meningitis (DIAM) in pa-
tients with NSCLC, treated with IV cetuximab.
CASE 1
A 78-year-old woman with a distant history of breast
cancer in remission was treated on clinical trial using con-
current cetuximab (400 mg/m2) and external beam radiother-
apy for stage IIIA NSCLC. Few hours after infusion, she
developed occipital and frontal headache, nausea, vomiting,
and neck stiffness. Computed tomography of head was non-
revealing, and cerebrospinal fluid (CSF) analysis showed
increased number of segmented polymorphonuclear leuko-
cytes at 459/l (87%), absence of malignant cells or xantho-
chromia, normal glucose, and modestly elevated protein lev-
els. The patient was started on broad-spectrum antibiotics
empirically. Once the infection was ruled out, antibiotics
were discontinued, and supportive care was provided. The
patient recovered without any residual neurologic sequelae.
CASE 2
A 59-year-old man with a remote history of orthotopic
liver transplant for alcoholic cirrhosis was started on systemic
treatment for metastatic NSCLC. He was admitted with acute
encephalopathy within few hours after the loading dose of
cetuximab (400 mg/m2). Computed tomography scan and
magnetic resonance imaging of the brain reported age-related
changes. Intravenous antibiotics were started for presumed
meningitis. CSF evaluation showed 214 nucleated cells, 15
red blood cells, 81 segmented cells, and seven lymphocytes;
glucose of 51 mg/dl and a total protein of 116 mg/dl; viral,
fungal, and bacterial cultures were negative. The patient
recovered neurologically within several days, and antibiotics
were discontinued.
DISCUSSION
The diagnosis of aseptic meningitis is based on clinical
picture, CSF cell count, and absence of bacterial and viral
findings. Most patients with aseptic meningitis are treated
with antibiotics, pending identification of infectious agent
and recover within 2 weeks, without any long-term neuro-
logic sequelae.
DIAM related to cetuximab was first reported in 2000
by Baselga et al.2 in patients with breast, ovarian, and colon
cancers with EGFR overexpression in a phase I clinical trial.
Feinstein et al.3 described two cases of DIAM in patients with
head and neck cancers treated with cetuximab. All patients
have recovered, and repeated infusion at the lower dose was
better tolerated after premedication with steroids. The authors
concluded that retreatment with cetuximab may be attempted
in situations where curative intent is feasible.
To our knowledge, these are the first cases of cetux-
imab-induced aseptic meningitis in patients with NSCLC
described in the literature. Although we cannot explain the
mechanism of this side effect, the clinical presentation, the
timing of the incidents relative to the cetuximab infusions,
and the diagnostic findings suggest that cetuximab may have
been implicated in the development of DIAM in two of our
patients. Introduction of a new or unapproved treatment with
a potential for significant morbidity in incurable situations
should be carefully weighed against the risks and effect on
quality of life. DIAM should be recognized as an entity with
steroids considered before loading cetuximab dose.4 This
report may serve as an additional reference for practitioners
using cetuximab.
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